Ashihara Eishi

アシハラエイシ | Ashihara Eishi

Affiliation and department：

Research field (1)： Pharmaceuticals - health and biochemistry

Research keywords (12)： γδT cell immunotherapy , Epigenetics , Nucleic acid medicine , drug delivery system , exosome , database analysis , Bromodomain proteins , Leukemia , caner immunotherapy , molecular targeting therapy , cancer stem cell , multiple myeloma

Research theme for competitive and other funds (22)：

2024 - 2027 Identification of novel target molecules against ALL and discovery of their seed compounds using open access data
2023 - 2027 Construction of pseudo-natural products using enzymes from medicinal plants and development of therapeutic agents for glioblastoma
2023 - 2024 新規作用機序に基づくクマリン系がん転移抑制薬の創製
2022 - 2023 新規作用機序に基づくクマリン系がん転移抑制薬の創製
2019 - 2022 Development of exosome-capturing antibody-conjugated nucleic acid medicines against multiple myeloma

2018 - 2021 Novel targeting system of circulating non-coding RNAs for the inhibition of cancer metastasis

2016 - 2019 Functional analysis of stem cell derived-Abeta phagocytic cells for the development of cell therapeutic strategies in Alzheimer's disease

2015 - 2018 Development of intravesical human gdT cell based immunotherapy against urinary bladder cancer cell

2014 - 2018 Development of non-operative treatment for local control and new bone formation against metastatic bone tumors

2014 - 2017 Development of a novel therapy against myeloma stem cells in a bone marrow hypoxic niche

2013 - 2016 The analysis of myeloid-derived suppressor cells related with the pathogenesis of rheumatoid arthritis and development of a new therapy

2011 - 2013 Development of new treatments against malignant bone and soft tissue tumors by using bisphosphonate and ionizing radiation

2011 - 2013 Analysis of myeloma stem cells and their niche

2011 - 2012 Challenging study of immunotherapy for osteosarcoma usingmicroparticles induced by photodynamic therapy

2009 - 2011 Eradication of chronic myelogenous leukemia stem cells and abnormal clone with T315I point mutation

2008 - 2011 Regulation of intracellular localization of ENaC by protease

2008 - 2010 Development of antibody-conjugatedβ-catenin siRNA therapy against multiple myeloma

2006 - 2008 Molecular therapeutics for imatinib-resistant Ph-positive leukemias with newly developed Bcr-Abl/Lyn tyrosine kinase inhibitor

2006 - 2007 Development ofa novel therapy for leukemia utilizing bisphcephonate triangle

2005 - 2006 表面プラズモン共鳴による革新的な輸血関連検査法の開発

2004 - 2005 ブラジル・おとぎり草から抽出した新規天然有機化合物(GUT-70)の抗腫瘍効果

1998 - 1999 末梢血幹細胞中の樹状細胞の誘導とその機能に関する研究

Show all

Papers (205)：

Ryo Inose, Ryota Goto, Shigekuni Hosogi, Eishi Ashihara, Yuichi Muraki. Occurrence of respiratory and urinary tract infections in patients treated with docetaxel compared with afatinib based on a health insurance claims database in Japan. International journal of clinical pharmacy. 2024
Takahiro Kitagawa, Takahiro Matsumoto, Tomoe Ohta, Tatsusada Yoshida, Youhei Saito, Yuji Nakayama, Yuki Hadate, Eishi Ashihara, Tetsushi Watanabe. Linderapyrone analogue LPD-01 as a cancer treatment agent by targeting importin7. Journal of Natural Medicines. 2024
Masato Yoshizawa, Atsushi Shiozaki, Eishi Ashihara. Depletion of DNTTIP2 Induces Cell Cycle Arrest in Pancreatic Cancer Cells. Cancer genomics & proteomics. 2024. 21. 1. 18-29
Daiki Shimizu, Miku Ishibashi, Tadaaki Yamada, Yuki Toda, Shigekuni Hosogi, Eishi Ashihara. POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma. Cancer genomics & proteomics. 2024. 21. 2. 158-165
Shota Oyama, Mao Tomita, Moeka Hata, Yu Mikame, Tsuyoshi Yamamoto, Eishi Ashihara, Asako Yamayoshi. Exosome-Hijacking Drug Delivery System with Branched Arginine Linker Effectively Deliver Antisense Oligonucleotides into Lung Adenocarcinoma Cells. Chemical & pharmaceutical bulletin. 2023. 71. 11. 819-823

ｍore...

MISC (115)：

北川翔大, 松本崇宏, 芦原英司, 渡辺徹志. 新規Wnt/β-catenin経路阻害剤linderapyroneおよびその誘導体のがん幹細胞増殖抑制作用. がん予防学術大会プログラム・抄録集. 2022. 2022
大村真穂, 友金眞光, 戸田侑紀, 細木誠之, 芦原英司. Butyrophilin3A1のγδT細胞の増幅効率の予測マーカーとしての有用性. 日本薬学会第141年会. 2021
松本崇宏, 北川翔大, 今堀大輔, 芦原英司, 渡辺徹志. Chemical structure, synthesis, and anti-proliferative activity of linderapyrone as a new Wnt signal inhibitor. 日本環境変異原ゲノム学会大会プログラム・要旨集. 2021. 50th
松本崇宏, 北川翔大, 今堀大輔, 太田智絵, 吉田達貞, 芦原英司, 渡辺徹志. クロモジ含有成分linderapyroneの化学構造,合成,およびwnt/β-catenin経路阻害活性評価. 日本生薬学会年会講演要旨集. 2021. 67th
谷口恵香, 谷口恵香, 影山進, 茂山千愛美, 安藤翔太, 飯居宏美, 芦原英司, 堀中真野, 酒井敏行, 河内明宏, et al. 新規がん予防標的GGCTは,がん細胞にHIF-1 alpha発現を誘導して好気性解糖を促進する. 日本衛生学雑誌(Web). 2021. 76. Supplement

ｍore...

Lectures and oral presentations (20)：

小児MLL関連白血病細胞株に対するBRD4およびCBP/p300阻害併用時におけるCBP/p300阻害作用機序別の細胞増殖抑制効果の比較
(第73回日本薬学会関西支部総会・大会 2023)
急性骨髄性白血病細胞に対するジペプチド型Wnt/β-catenin経路阻害剤の抗腫瘍効果の検討
(第82回日本癌学会学術総会 2023)
4T1.2より分泌される細胞外小胞は糖代謝リプログラミングにより肺組織酸性化を誘導する
(第82回日本癌学会学術総会 2023)
BRD4/CBP/p300マルチブロモドメイン阻害の小児MLL遺伝子関連ALLに対する有効性の検証
(第17回次世代を担う若手のための医療薬科学シンポジウム 2023)
人参由来成分KPU-230はエストロゲン受容体を介してマウス気道粘液線毛クリアランスを活性化する
(第17回次世代を担う若手のための医療薬科学シンポジウム 2023)

ｍore...

Education (1)：

1981 - 1987 Kyoto Prefectural University of Medicine

Professional career (2)：

PhD. Med. Sci. (Kyoto Prefectural University of Medicine)
PhD. Pharm. Sci. (Kyoto Pharmaceutical University)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page